Literature DB >> 18762956

Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10).

Karen Fritchie1, Eija Siintola, Diane Armao, Anna-Elina Lehesjoki, Thomas Marino, Cynthia Powell, Michael Tennison, Jessica M Booker, Sabine Koch, Sanna Partanen, Kinuko Suzuki, Jaana Tyynelä, Leigh B Thorne.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) are autosomal recessively inherited disorders collectively considered to be one among the most common pediatric neurodegenerative lysosomal storage diseases. Four main clinical subtypes have been described based on the age at presentation: infantile, late infantile, juvenile and adult types. In addition, rare congenital cases of NCL have been reported in the literature. Previously, a homozygous mutation in the cathepsin D gene has been shown to cause congenital NCL in a patient of Pakistani origin. We report a case of a 39-week estimated gestational age female infant with severe microcephaly and hypertonia, whereas MRI showed generalized hypoplasia of the cerebral and cerebellar hemispheres. The infant died on day two after birth. Postmortem examination revealed a small, firm brain with extensive neuronal loss and gliosis. Remaining neurons, astrocytes and macrophages contained PAS-positive storage material with granular ultrastructure and immunoreactivity against sphingolipid activator protein D. A diagnosis of congenital NCL was rendered with a novel mutation, c.299C > T (p.Ser100Phe) in exon 3 of the cathepsin D gene. In the patient fibroblasts, cathepsin D activity was marginal, but the protein appeared stable and normally processed. This was confirmed in overexpression studies. Importantly, by identification of the mutation in the family, we were able to confirm the first prenatal diagnosis excluding cathepsin D deficiency in the younger sibling of the patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762956     DOI: 10.1007/s00401-008-0426-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  18 in total

1.  Neuronal ceroid lipofuscinosis: genetic and phenotypic spectrum of 14 patients from Turkey.

Authors:  Melis Kose; Engin Kose; Aycan Ünalp; Ünsal Yılmaz; Selvinaz Edizer; Hande Gazeteci Tekin; Pakize Karaoğlu; Taha Reşid Özdemir; Esra Er; Hüseyin Onay; Eser Sozmen Yildirim
Journal:  Neurol Sci       Date:  2021-01-23       Impact factor: 3.307

2.  CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis.

Authors:  Zinayida Shevtsova; Manuel Garrido; Jochen Weishaupt; Paul Saftig; Mathias Bähr; Fred Lühder; Sebastian Kügler
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 3.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

Review 4.  Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia.

Authors:  Jun Yup Lee; Oana C Marian; Anthony S Don
Journal:  Neuromolecular Med       Date:  2021-02-07       Impact factor: 3.843

5.  Morphologic and functional correlates of synaptic pathology in the cathepsin D knockout mouse model of congenital neuronal ceroid lipofuscinosis.

Authors:  Sabine Koch; Svetlana M Molchanova; Ann K Wright; Andrew Edwards; Jonathan D Cooper; Tomi Taira; Thomas H Gillingwater; Jaana Tyynelä
Journal:  J Neuropathol Exp Neurol       Date:  2011-12       Impact factor: 3.685

6.  Early infantile neuronal ceroid lipofuscinosis (CLN10 disease) associated with a novel mutation in CTSD.

Authors:  Stefano Doccini; Stefano Sartori; Stefan Maeser; Francesco Pezzini; Sara Rossato; Francesca Moro; Irene Toldo; Michael Przybylski; Filippo M Santorelli; Alessandro Simonati
Journal:  J Neurol       Date:  2016-04-12       Impact factor: 4.849

Review 7.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

8.  Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology.

Authors:  Joshua Hersheson; Derek Burke; Robert Clayton; Glenn Anderson; Thomas S Jacques; Philippa Mills; Nicholas W Wood; Paul Gissen; Peter Clayton; Julian Fearnley; Sara E Mole; Henry Houlden
Journal:  Neurology       Date:  2014-10-08       Impact factor: 9.910

Review 9.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

10.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Authors:  Valerie Cullen; Maria Lindfors; Juliana Ng; Anders Paetau; Erika Swinton; Piotr Kolodziej; Heather Boston; Paul Saftig; John Woulfe; Mel B Feany; Liisa Myllykangas; Michael G Schlossmacher; Jaana Tyynelä
Journal:  Mol Brain       Date:  2009-02-09       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.